- cafead   Oct 30, 2023 at 08:12: PM
via Ahead of a Tuesday advisory committee meeting, FDA staff have called into question the safety risk testing for Vertex Pharmaceuticals and CRISPR Therapeutics’ investigational sickle cell disease therapy exagamglogene autotemcel (exa-cel).
article source
article source